Selective modulation through the glucocorticoid receptor ameliorates muscle pathology in mdx mice

Journal of Pathology

Volumn 231, Issue 2, 2013, Pages 223-235

  Huynh, Tony ^a   Uaesoontrachoon, Kitipong ^a   Quinn, James L ^a   Tatem, Kathleen S ^a   Heier, Christopher R ^a   Van Der Meulen, Jack H ^a   Yu, Qing ^a   Harris, Mark ^b   Nolan, Christopher J ^c   Haegeman, Guy ^d   Grounds, Miranda D ^e   Nagaraju, Kanneboyina ^a  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b MATER CHILDREN S HOSPITAL   (Australia)

^c The Australian National University   (Australia)

^d GHENT UNIVERSITY   (Belgium)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

compound A; Duchenne muscular dystrophy; glucocorticoid receptor; glucocorticoids; transrepression NF B

Indexed keywords

ATROGIN 1; CATHEPSIN B; CCL2 PROTEIN; CREATINE KINASE; DYSTROPHIN; GAMMA INTERFERON; GLUCOCORTICOID RECEPTOR; IGF1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12P70; INTERLEUKIN 6; MSTN PROTEIN; OSTEOPONTIN; PREDNISOLONE; PROTEIN; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR FKHRL1; TRIM63 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CREATINE KINASE BLOOD LEVEL; DUCHENNE MUSCULAR DYSTROPHY; EMBRYO; ENZYME ACTIVITY; EXTENSOR DIGITORUM LONGUS MUSCLE; FORELIMB; GASTROCNEMIUS MUSCLE; GENE EXPRESSION; GLYCOGEN MUSCLE LEVEL; GRIP STRENGTH; HINDLIMB; IN VITRO STUDY; MALE; MODULATION; MOUSE; MYOBLAST; MYOTUBE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TIBIALIS ANTERIOR MUSCLE; WEIGHT REDUCTION; WILD TYPE;

COMPOUND A; DUCHENNE MUSCULAR DYSTROPHY; GLUCOCORTICOID RECEPTOR; GLUCOCORTICOIDS; TRANSREPRESSION NF-ΚB;

ACETATES; ANIMALS; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; MALE; MICE; MICE, INBRED MDX; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; NF-KAPPA B; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, GLUCOCORTICOID; TYRAMINE;

EID: 84883888613     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4231     Document Type: Article

References (65)

1. Hoffman EP, Brown RH Jr, et al., Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987; 51: 919-928.
2. Bushby K, Finkel R, Birnkrant DJ, et al., Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010; 9: 77-93.
3. Bushby K, Finkel R, Birnkrant DJ, et al., Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 2010; 9: 177-189.
4. Gumerson JD, Michele DE,. The dystrophin-glycoprotein complex in the prevention of muscle damage. J Biomed Biotechnol 2011; 2011: 210797.
5. Manzur AY, Kuntzer T, Pike M, et al., Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 2008: CD003725.
6. Pivonello R, De Martino MC, De Leo M, et al., Cushing's syndrome. Endocrinol Metab Clin North Am 2008; 37: 135-149, ix.
7. De Bosscher K, Haegeman G,. Minireview: latest perspectives on antiinflammatory actions of glucocorticoids. Mol Endocrinol 2009; 23: 281-291.
8. Evans NP, Misyak SA, Robertson JL, et al., Immune-mediated mechanisms potentially regulate the disease time-course of Duchenne muscular dystrophy and provide targets for therapeutic intervention. PMR 2009; 1: 755-768.
9. Monici MC, Aguennouz M, Mazzeo A, et al., Activation of nuclear factor-κB in inflammatory myopathies and Duchenne muscular dystrophy. Neurology 2003; 60: 993-997.
10. Kumar A, Boriek AM,. Mechanical stress activates the nuclear factor-κB pathway in skeletal muscle fibers: a possible role in Duchenne muscular dystrophy. FASEB J 2003; 17: 386-396.
11. Messina S, Vita GL, Aguennouz M, et al., Activation of NF-κB pathway in Duchenne muscular dystrophy: relation to age. Acta Myol 2011; 30: 16-23.
12. Reay DP, Yang M, Watchko JF, et al., Systemic delivery of NEMO binding domain/IKKγ inhibitory peptide to young mdx mice improves dystrophic skeletal muscle histopathology. Neurobiol Dis 2011; 43: 598-608.
13. Peterson JM, Kline W, Canan BD, et al., Peptide-based inhibition of NF-κB rescues diaphragm muscle contractile dysfunction in a murine model of Duchenne muscular dystrophy. Mol Med 2011; 17: 508-515.
14. Tang Y, Reay DP, Salay MN, et al., Inhibition of the IKK/NF-κB pathway by AAV gene transfer improves muscle regeneration in older mdx mice. Gene Ther 2010; 17: 1476-1483.
15. Acharyya S, Villalta SA, Bakkar N, et al., Interplay of IKK/NF-κB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J Clin Invest 2007; 117: 889-901.
16. Messina S, Bitto A, Aguennouz M, et al., The soy isoflavone genistein blunts nuclear factor-κB, MAPKs and TNFα activation and ameliorates muscle function and morphology in mdx mice. Neuromusc Disord 2011; 21: 579-589.
17. Evans NP, Call JA, Bassaganya-Riera J, et al., Green tea extract decreases muscle pathology and NF-κB immunostaining in regenerating muscle fibers of mdx mice. Clin Nutr 2010; 29: 391-398.
18. Siegel AL, Bledsoe C, Lavin J, et al., Treatment with inhibitors of the NF-κB pathway improves whole body tension development in the mdx mouse. Neuromusc Disord 2009; 19: 131-139.
19. Pan Y, Chen C, Shen Y, et al., Curcumin alleviates dystrophic muscle pathology in mdx mice. Mol Cells 2008; 25: 531-537.
20. Messina S, Bitto A, Aguennouz M, et al., Nuclear factor-κB blockade reduces skeletal muscle degeneration and enhances muscle function in mdx mice. Exp Neurol 2006; 198: 234-241.
21. Messina S, Altavilla D, Aguennouz M, et al., Lipid peroxidation inhibition blunts nuclear factor-κB activation, reduces skeletal muscle degeneration, and enhances muscle function in mdx mice. Am J Pathol 2006; 168: 918-926.
22. De Bosscher K, Van den Berghe W, Beck IM, et al., A fully dissociated compound of plant origin for inflammatory gene repression. Proc Natl Acad Sci USA 2005; 102: 15827-15832.
23. Dewint P, Gossye V, De Bosscher K, et al., A plant-derived ligand favoring monomeric glucocorticoid receptor conformation with impaired transactivation potential attenuates collagen-induced arthritis. J Immunol 2008; 180: 2608-2615.
24. Gossye V, Elewaut D, Van Beneden K, et al., A plant-derived glucocorticoid receptor modulator attenuates inflammation without provoking ligand-induced resistance. Ann Rheum Dis 2009; 69: 291-296.
25. Gossye V, Elewaut D, Bougarne N, et al., Differential mechanism of NF-κB inhibition by two glucocorticoid receptor modulators in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2009; 60: 3241-3250.
26. Robertson S, Allie-Reid F, Vanden Berghe W, et al., Abrogation of glucocorticoid receptor dimerization correlates with dissociated glucocorticoid behavior of compound a. J Biol Chem 2010; 285: 8061-8075.
27. van Loo G, Sze M, Bougarne N, et al., Antiinflammatory properties of a plant-derived, non-steroidal dissociated glucocorticoid receptor modulator in experimental autoimmune encephalomyelitis. Mol Endocrinol 2010; 24: 310-322.
28. Reber LL, Daubeuf F, Plantinga M, et al., A dissociated glucocorticoid receptor modulator reduces airway hyperresponsiveness and inflammation in a mouse model of asthma. J Immunol 2012; 188: 3478-3487.
29. Rauner M, Goettsch C, Stein N, et al., Dissociation of osteogenic and immunological effects by the selective glucocorticoid receptor agonist, compound A, in human bone marrow stromal cells. Endocrinology 2011; 152: 103-112.
30. Rauch A, Gossye V, Bracke D, et al., An anti-inflammatory selective glucocorticoid receptor modulator preserves osteoblast differentiation. FASEB J 2011; 25: 1323-1332.
31. De Bosscher K, Vanden Berghe W, Haegeman G,. Crosstalk between nuclear receptors and nuclear factor-κB. Oncogene 2006; 25: 6868-6886.
32. Reagan-Shaw S, Nihal M, Ahmad N,. Dose translation from animal to human studies revisited. FASEB J 2008; 22: 659-661.
33. Sali A, Guerron AD, Gordish-Dressman H, et al., Glucocorticoid-treated mice are an inappropriate positive control for long-term preclinical studies in the mdx mouse. PLoS One 2012; 7: e34204.
34. Spurney CF, Gordish-Dressman H, Guerron AD, et al., Preclinical drug trials in the mdx mouse: assessment of reliable and sensitive outcome measures. Muscle Nerve 2009; 39: 591-602.
35. Morgan JE, Beauchamp JR, Pagel CN, et al., Myogenic cell lines derived from transgenic mice carrying a thermolabile T antigen: a model system for the derivation of tissue-specific and mutation-specific cell lines. Dev Biol 1994; 162: 486-498.
36. Jat PS, Noble MD, Ataliotis P, et al., Direct derivation of conditionally immortal cell lines from an H-2Kb-tsA58 transgenic mouse. Proc Natl Acad Sci USA 1991; 88: 5096-5100.
37. Reiter MH, Vila G, Knosp E, et al., Opposite effects of serum- and glucocorticoid-regulated kinase-1 and glucocorticoids on POMC transcription and ACTH release. Am J Physiol Endocrinol Metab 2011; 301: E336-341.
38. Rayavarapu S, Coley W, Cakir E, et al., Identification of disease specific pathways using in vivo SILAC proteomics in dystrophin-deficient mdx mouse. Mol Cell Proteom 2013; 12: 1061-73.
39. Baudy AR, Sali A, Jordan S, et al., Non-invasive optical imaging of muscle pathology in mdx mice using cathepsin caged near-infrared imaging. Mol Imaging Biol 2011; 13: 462-470.
40. Radley HG, Grounds MD,. Cromolyn administration (to block mast cell degranulation) reduces necrosis of dystrophic muscle in mdx mice. Neurobiol Dis 2006; 23: 387-397.
41. Grounds MD, Radley HG, Lynch GS, et al., Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy. Neurobiol Dis 2008; 31: 1-19.
42. Willmann R, De Luca A, Benatar M, et al., Enhancing translation: guidelines for standard pre-clinical experiments in mdx mice. Neuromuscul Disord 2012; 22: 43-49.
43. Tidball JG,. Inflammation in skeletal muscle regeneration. In Skeletal Muscle Repair and Regeneration, Schiaffino S, (ed.). Springer Science and Business Media: Dordrecht, 2008; 243-268.
44. Marques MJ, Ventura Machado R, Minatel E, et al., Disodium cromoglycate protects dystrophin-deficient muscle fibers from leakiness. Muscle Nerve 2008; 37: 61-67.
45. Granchelli JA, Avosso DL, Hudecki MS, et al., Cromolyn increases strength in exercised mdx mice. Res Commun Mol Pathol Pharmacol 1996; 91: 287-296.
46. Saffar AS, Ashdown H, Gounni AS,. The molecular mechanisms of glucocorticoids-mediated neutrophil survival. Curr Drug Targets 2011; 12: 556-562.
47. Serrano AL, Mann CJ, Vidal B, et al., Cellular and molecular mechanisms regulating fibrosis in skeletal muscle repair and disease. Curr Top Dev Biol 2011; 96: 167-201.
48. Mann CJ, Perdiguero E, Kharraz Y, et al., Aberrant repair and fibrosis development in skeletal muscle. Skelet Muscle 2011; 1: 21.
49. McLennan IS,. Degenerating and regenerating skeletal muscles contain several subpopulations of macrophages with distinct spatial and temporal distributions. J Anat 1996; 188 (1): 17-28.
50. Liberman AC, Druker J, Refojo D, et al., Glucocorticoids inhibit GATA-3 phosphorylation and activity in T cells. FASEB J 2009; 23: 1558-1571.
51. Liberman AC, Antunica-Noguerol M, Ferraz-de-Paula V, et al., Compound A, a dissociated glucocorticoid receptor modulator, inhibits T-bet (Th1) and induces GATA-3 (Th2) activity in immune cells. PLoS One 2012; 7: e35155.
52. Ruff RL, Weissmann J,. Endocrine myopathies. Neurol Clin 1988; 6: 575-592.
53. Cai D, Frantz JD, Tawa NE, Jr,., et al. IKKβ/NF-κB activation causes severe muscle wasting in mice. Cell 2004; 119: 285-298.
54. Mourkioti F, Kratsios P, Luedde T, et al., Targeted ablation of IKK2 improves skeletal muscle strength, maintains mass, and promotes regeneration. J Clin Invest 2006; 116: 2945-2954.
55. Mammucari C, Schiaffino S, Sandri M,. Downstream of Akt: FoxO3 and mTOR in the regulation of autophagy in skeletal muscle. Autophagy 2008; 4: 524-526.
56. Ma K, Mallidis C, Bhasin S, et al., Glucocorticoid-induced skeletal muscle atrophy is associated with upregulation of myostatin gene expression. Am J Physiol Endocrinol Metab 2003; 285: E363-371.
57. Amthor H, Hoogaars WM,. Interference with myostatin/ActRIIB signaling as a therapeutic strategy for Duchenne muscular dystrophy. Curr Gene Ther 2012; 12: 245-259.
58. Sriram S, Subramanian S, Sathiakumar D, et al., Modulation of reactive oxygen species in skeletal muscle by myostatin is mediated through NF-κB. Aging Cell 2011; 10: 931-948.
59. Clemmons DR,. Role of IGF-I in skeletal muscle mass maintenance. Trends Endocrinol Metab 2009; 20: 349-356.
60. Shavlakadze T, Chai J, Maley K, et al., A growth stimulus is needed for IGF-1 to induce skeletal muscle hypertrophy in vivo. J Cell Sci 2010; 123: 960-971.
61. Gayan-Ramirez G, Vanderhoydonc F, Verhoeven G, et al., Acute treatment with corticosteroids decreases IGF-1 and IGF-2 expression in the rat diaphragm and gastrocnemius. Am J Respir Crit Care Med 1999; 159: 283-289.
62. Schakman O, Gilson H, Kalista S, et al., Mechanisms of muscle atrophy induced by glucocorticoids. Horm Res 2009; 72 (suppl 1): 36-41.
63. Vetrone SA, Montecino-Rodriguez E, Kudryashova E, et al., Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGFβ. J Clin Invest 2009; 119: 1583-1594.
64. Zanotti S, Gibertini S, Di Blasi C, et al., Osteopontin is highly expressed in severely dystrophic muscle and seems to play a role in muscle regeneration and fibrosis. Histopathology 2011; 59: 1215-1228.
65. Uaesoontrachoon K, Wasgewatte Wijesinghe DK, Mackie EJ, et al., Osteopontin deficiency delays inflammatory infiltration and the onset of muscle regeneration in a mouse model of muscle injury. Dis Model Mech 2012; 6: 197-205 (e-pub).